BioCardia, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
BioCardia, Inc. (BCDA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.29 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-12
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2026-03-31 was $1.29.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $2.02, a 56.37% decline year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $4.63, a 13.13% decline year-over-year.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2020-03-31 was $5.33.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.37, a 48.30% decline from fiscal 2024.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $2.65, a 87.29% decline from fiscal 2023.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $20.85, a 1245.16% increase from fiscal 2022.
- BioCardia, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $1.55, a 56.46% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month as first filed | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.29 10-Q · filed 2026-08-12 | ||||||
| 2026-03-31 | $1.29 10-Q · filed 2026-05-15 | ||||||
| 2025-12-31 | $1.37 10-K · filed 2026-03-24 | ||||||
| 2024-12-31 | $2.65 10-K · filed 2026-03-24 | ||||||
| 2024-09-30 | $33.97 10-Q · filed 2024-11-13 | ||||||
| 2024-06-30 | $33.97 10-Q · filed 2024-08-13 | ||||||
| 2023-12-31 | $20.85 10-K · filed 2025-03-26 | $1.39 10-K · filed 2024-03-27 | |||||
| 2023-09-30 | $2.26 10-Q · filed 2024-05-14 | $1.69 10-Q · filed 2023-11-08 | |||||
| 2023-06-30 | $1.69 10-Q · filed 2023-08-09 | ||||||
| 2022-12-31 | $1.55 10-K · filed 2023-03-29 | ||||||
| 2022-09-30 | $1.54 10-Q · filed 2022-11-09 | ||||||
| 2022-06-30 | $1.53 10-Q · filed 2022-08-10 | ||||||
| 2022-03-31 | $2.02 10-Q · filed 2022-05-11 | ||||||
| 2021-12-31 | $3.56 10-K · filed 2022-03-29 | ||||||
| 2021-09-30 | $3.56 10-Q · filed 2021-11-10 | ||||||
| 2021-06-30 | $3.61 10-Q · filed 2021-08-12 | ||||||
| 2021-03-31 | $4.63 10-Q · filed 2021-05-13 | ||||||
| 2020-12-31 | $3.10 10-K · filed 2021-03-30 | ||||||
| 2020-09-30 | $3.15 10-Q · filed 2020-11-10 | ||||||
| 2020-06-30 | $3.15 10-Q · filed 2020-08-13 | ||||||
| 2020-03-31 | $5.33 10-Q · filed 2020-05-15 | ||||||
| 2020-01-29 | $5.32 10-K · filed 2022-03-29 | ||||||
| 2019-12-31 | $5.28 10-K · filed 2020-04-09 | ||||||
| 2019-09-30 | $5.28 10-Q · filed 2019-11-19 | ||||||
| 2019-06-30 | $10.05 10-Q · filed 2019-08-14 | ||||||
| 2018-12-31 | $2.41 10-K · filed 2019-04-02 | ||||||
| 2018-09-30 | $2.41 10-Q · filed 2018-11-08 | ||||||
| 2018-06-30 | $2.48 10-Q · filed 2018-08-09 | ||||||
| 2018-03-31 | $2.60 10-Q · filed 2018-05-10 | ||||||
| 2017-12-31 | $7.66 10-K · filed 2018-03-16 | ||||||
| 2017-09-30 | $8.34 10-Q · filed 2017-11-09 | ||||||
| 2017-06-30 | $0.73 10-Q · filed 2017-08-14 | ||||||
| 2017-03-31 | $0.90 10-Q · filed 2017-05-11 | ||||||
| 2016-12-31 | $0.15 10-K · filed 2017-03-30 | ||||||
| 2016-09-30 | $0.00 10-Q · filed 2016-10-17 | ||||||
| 2016-06-30 | $0.00 10-Q · filed 2016-08-02 | ||||||
| 2016-03-31 | $0.00 10-Q · filed 2016-05-03 | ||||||
| 2015-12-31 | $0.00 10-K · filed 2016-03-25 | ||||||
| 2015-09-30 | $0.00 10-Q · filed 2015-10-29 | ||||||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-12 | ||||||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-12 | ||||||
| 2014-12-31 | $0.00 10-K · filed 2015-03-24 | ||||||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-06 | ||||||
| 2014-06-30 | $0.00 10-Q · filed 2014-08-06 | ||||||
| 2014-03-31 | $0.00 10-Q · filed 2014-05-12 | ||||||
| 2013-12-31 | $0.00 10-K · filed 2014-03-24 | ||||||
| 2013-09-30 | $0.00 10-Q · filed 2013-11-01 | ||||||
| 2013-06-30 | $0.00 10-Q · filed 2013-07-26 | ||||||
| 2012-12-31 | $0.00 10-K · filed 2014-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |